Get started
Author

Kostas Galanis

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
2020 · George V. Papatheodoridis, Vana Sypsa, et al. · Journal of Hepatology · 107
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
2020 · George V. Papatheodoridis, George N. Dalekos, et al. · Journal of Hepatology · 92
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B
2021 · George V. Papatheodoridis, George N. Dalekos, et al. · JHEP Reports · 9
PDF
Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results from the PAGE-B cohort
2026 · George V. Papatheodoridis, George Dalekos, et al. · Journal of Hepatology · 3
Nursing Assessment and Management of Pain in Infants
2016 · Jennifer Kostiander, Kostas Galanis · 1
OS-104 Outcomes beyond 10 years in entecavir or tenofovir treated Caucasian chronic hepatitis B patients of the real-life PAGE-B cohort
2025 · George Papatheodoridis, George Dalekos, et al. · Journal of Hepatology
PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy
2020 · George Papatheodoridis, George Dalekos, et al. · Journal of Hepatology
PDF
FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients
2019 · George Papatheodoridis, George Dalekos, et al. · Journal of Hepatology
Works count: 8
Citation count: 212
H-index: 3
I10-index: 2
Year
Topic
Type